Cipla Ltd

Products

Full Paper

Full Paper

Price: £95.00
Description: The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.



Research Report Overview

Published Date: 22/02/2012
Category: Therapies & Markets

Research Report Decription

Cipla Ltd - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.

Features:

  •  Provides all the crucial information on Cipla Limited required for business and competitor intelligence needs
  • Contains a study of the major internal and external factors affecting Cipla Limited in the form of a SWOT analysis as well as a breakdown and examination of leading product revenue streams of Cipla Limited
  • Data is supplemented with details on Cipla Limited history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available statement from Cipla Limited

Key Questions Answered:

  • Gain understanding of the Cipla Limited and the factors that influence its strategies 
  • Track strategic initiatives of the company and latest corporate news and actions 
  • Assess Cipla Limited as a prospective partners, vendor or supplier
  • Support sales activities by understanding your customers' businesses better
  • Stay up to date on Cipla Limited’s business structure, strategy and prospects

Companies Mentioned:

Cipla Ltd

Paper Highlights:

Cipla is engaged in manufacturing prescription drugs, animal products, OTC (over-the-counter) products, bulk drugs, flavors and fragrances, and agrochemicals. The company operates in India, where it is headquartered in Mumbai, Maharashtra.  The company recorded revenues of INR64,338.8 million (approximately $1,402.6 million) during the financial year ended March 2011 (FY2011), an increase of 12.6% over FY2010. The operating profit of the company was INR13,853.9 million (approximately $302 million) during FY2011, a decrease of 2.3% compared with FY2010. The net profit was INR9,603.9 million (approximately $209.4 million) in FY2011, a decrease of 11.2% compared with FY2010.